Literature DB >> 10703759

Treatment of severe depression.

M E Thase1.   

Abstract

A significant minority of depressed outpatients and a vast majority of those hospitalized for depression can be considered severely ill. Severe depressive states are quite heterogeneous and include the more classical subforms (e.g., melancholia or psychotic depression) as well as various comorbid presentations. This article reviews the classification, phenomenology, pathophysiology, and treatment of severe depression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10703759

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  14 in total

Review 1.  The small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists?

Authors:  Michael E Thase
Journal:  Curr Psychiatry Rep       Date:  2011-12       Impact factor: 5.285

2.  Retention in depression treatment among ethnic and racial minority groups in the United States.

Authors:  Lisa R Fortuna; Margarita Alegria; Shan Gao
Journal:  Depress Anxiety       Date:  2010-05       Impact factor: 6.505

Review 3.  Stress and health: psychological, behavioral, and biological determinants.

Authors:  Neil Schneiderman; Gail Ironson; Scott D Siegel
Journal:  Annu Rev Clin Psychol       Date:  2005       Impact factor: 18.561

4.  Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.

Authors:  Sidney H Kennedy; Henning F Andersen; Raymond W Lam
Journal:  J Psychiatry Neurosci       Date:  2006-03       Impact factor: 6.186

5.  A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.

Authors:  Frances R Levin; John Mariani; Daniel J Brooks; Martina Pavlicova; Edward V Nunes; Vito Agosti; Adam Bisaga; Maria A Sullivan; Kenneth M Carpenter
Journal:  Addiction       Date:  2013-03-21       Impact factor: 6.526

6.  Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine.

Authors:  Anjana Bose; Joyce Tsai; Dayong Li
Journal:  Clin Drug Investig       Date:  2012-06-01       Impact factor: 2.859

Review 7.  Severe depression: is there a best approach?

Authors:  S B Sonawalla; M Fava
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

8.  Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.

Authors:  Alan G Wade; José-Luis Fernández; Clément François; Karina Hansen; Natalya Danchenko; Nicolas Despiegel
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence.

Authors:  Kenneth M Carpenter; David McDowell; Daniel J Brooks; Wendy Y Cheng; Frances R Levin
Journal:  Am J Addict       Date:  2009 Jan-Feb

Review 10.  Vagus nerve stimulation for epilepsy and depression.

Authors:  Andrew H Milby; Casey H Halpern; Gordon H Baltuch
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.